Next Article in Journal
The History and Science of the Major Birch Pollen Allergen Bet v 1
Next Article in Special Issue
Regulation of Phosphoinositide Signaling by Scaffolds at Cytoplasmic Membranes
Previous Article in Journal
Notes from the Underground: Heme Homeostasis in C. elegans
Previous Article in Special Issue
Nuclear Phosphoinositides as Key Determinants of Nuclear Functions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 13
Issue 7
10.3390/biom13071150
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Assigning the Absolute Configuration of Inositol Poly- and Pyrophosphates by NMR Using a Single Chiral Solvating Agent

by
Kevin Ritter
1,
Nikolaus Jork
1,2,
Anne-Sophie Unmüßig
1,
Maja Köhn
2,3,4 and
Henning J. Jessen
1,2,*
1
Institute of Organic Chemistry, University of Freiburg, 79104 Freiburg, Germany
2
CIBSS—Centre for Integrative Biological Signalling Studies, University of Freiburg, 79104 Freiburg, Germany
3
Institute of Biology 3, Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany
4
BIOSS—Centre for Biological Signalling Studies, University of Freiburg, 79104 Freiburg, Germany
*
Author to whom correspondence should be addressed.
Biomolecules 2023, 13(7), 1150; https://doi.org/10.3390/biom13071150
Submission received: 30 May 2023 / Revised: 11 July 2023 / Accepted: 14 July 2023 / Published: 19 July 2023
(This article belongs to the Special Issue Versatility of a Cellular Signaling Scaffold: The Inositol Ring Rules! – Honorary Special Issue Commemorating the Work of Prof. Lucio I. M. Cocco)
Browse Figures
Review Reports Versions Notes

Abstract

:
Inositol phosphates constitute a family of highly charged messenger molecules that play diverse roles in cellular processes. The various phosphorylation patterns they exhibit give rise to a vast array of different compounds. To fully comprehend the biological interconnections, the precise molecular identification of each compound is crucial. Since the myo-inositol scaffold possesses an internal mirror plane, enantiomeric pairs can be formed. Most commonly employed methods for analyzing InsPs have been geared towards resolving regioisomers, but they have not been capable of resolving enantiomers. In this study, we present a general approach for enantiomer assignment using NMR measurements. To achieve this goal, we used 31P-NMR in the presence of L-arginine amide as a chiral solvating agent, which enables the differentiation of enantiomers. Using chemically synthesized standard compounds allows for an unambiguous assignment of the enantiomers. This method was applied to highly phosphorylated inositol pyrophosphates, as well as to lowly phosphorylated inositol phosphates and bisphosphonate analogs. Our method will facilitate the assignment of biologically relevant isomers when isolating naturally occurring compounds from biological specimens.

1. Introduction

Inositol phosphates are a family of cellular messenger molecules involved in numerous processes in eukaryotic cells [1,2,3,4,5,6,7]. The highly charged molecules constitute a sophisticated signaling network and are associated with important functions such as energy and phosphate homeostasis as well as exocytotic events. The molecular scaffold of these messengers is myo-inositol (1), a cyclohexane hexa-ol structure with a distinct 3D arrangement of the groups. A generally applied assignment of the positions at the ring originates from another subclass of inositol phosphates, the phosphatidyl inositol phosphates, where the glycerol backbone is attached to the 1 position of the inositol (numbering see Figure 1). The remaining positions are numbered counterclockwise. The mirror plane through the 2 and 5 positions of the molecule renders it a meso-compound, which is optically inactive and achiral. The introduction of groups outside of the mirror plane leads to a desymmetrization of the molecule and therefore to the formation of enantiomeric pairs. By combinatorial attachment of phosphate groups to the inositol ring, 63 different inositol phosphate derivatives are possible [8]. By introducing further phosphate groups to inositol hexakisphosphate (InsP6), forming phosphoanhydride bonds, inositol pyrophosphates (PP-InsPs) are formed. One additional phosphate group generates PP-InsP5 (also often abbreviated as InsP7). Six different PP-InsP5 isomers are possible, including two enantiomeric pairs (1/3-PP-InsP5 and 4/6-PP-InsP5), whereas the remaining two are achiral meso-compounds (Figure 1). By introducing another pyrophosphate group, 15 different (PP)2-InsP4 regioisomers (also often abbreviated as InsP8) are possible, including six pairs of enantiomers. Of note, both 1/3-PP-InsP5 and 4/6-PP-InsP5 have been identified in biological systems [9,10,11,12,13,14,15].
It becomes clear that there is a large number of different inositol phosphates depending on the number of phosphate groups and the positions where they are attached. To understand connections within the complex signaling network of inositol phosphates, accurate structural assignment is of great importance. In addition to the variety of different isomers, the absence of chromophores and low concentration in cells are major hurdles for accurate assignments. Different methods were established to analyze structures and concentrations of inositol phosphates even in a complex mixture or by previous enrichment. In the last few decades, the most commonly applied method relied on radiolabeling by using tritiated [3H]-inositol in combination with SAX-HPLC and subsequent scintillation counting. Gel electrophoresis (PAGE) is an alternative method that is inexpensive and readily available. Although it can separate higher InsPs, it has great difficulty distinguishing between PP-InsP regioisomers [16]. In 2020, we introduced the capillary electrophoresis electrospray ionization mass spectrometry (CE-ESI-MS) method combined with stable isotopic labeled standards, which enables accurate assignments without radiolabeling [17]. However, all of the presented methods have in common that they are only able to distinguish between regioisomers but not between enantiomers.
Another method for assigning biologically relevant isomers is based on NMR measurements. InsPs are isolated from enzymatic reactions or cell lysates, and in combination with chemically synthesized InsP standards, NMR spiking experiments are conducted [15,18,19,20]. But again, this method is not able to discriminate between enantiomers since the compounds are in an achiral environment and therefore the resonance signals of enantiomers are recorded at identical chemical shifts. A comparison of optical rotation values is not possible as those values are usually very small, are strongly pH-value-dependent, and require very high purity.
Yet, there are also methods that are capable of discriminating not only between regioisomers, but also between enantiomers. One method involves crystallization experiments. For instance, the naturally occurring (PP)2-InsP4 enantiomer was identified in crystal complexes of the kinase domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) [14,21]. Using a combination of enantiopure synthetic standards and enzyme assays, it is also possible to reveal the identity of biologically relevant isomers [22]. Recently the Fiedler group demonstrated the viability of enantiomer assignment by applying enantiopure [13C1]- and [13C2]-labeled myo-inositols in combination with 13C-, 31P-, and two-dimensional-NMR measurements [23].
Blüher et al. introduced an easy way to discriminate between InsP5 enantiomers using NMR spectroscopy by adding an enantiopure chiral solvation agent [24]. A chiral environment is generated, and the formation of diastereomeric ion pairs consisting of the respective InsPs and the shift reagent results in slightly different shifts for each enantiomer in 31P-NMR. By spiking with enantiopure standard compounds, an assignment is possible, yet it requires significant amounts of analyte on the order of 10–100 micrograms. Since it is known that phosphates interact strongly with guanidium groups, several compounds containing such groups were screened. It was found that commercially available L-arginine amide hydrochloride (8, L-ArgNH2 * HCl) is a suitable chiral solvating agent for 1/3-OH InsP5 (Figure 2) [24].
In this work, we extend this approach to PP-InsPs and to nonhydrolyzable PCP-InsP analogs that carry a bisphosphonate moiety (PCP) [25,26]. We also synthesized several model compounds to show the scope and limitations of the method concerning the phosphorylation density of the InsPs.

2. Materials and Methods

2.1. Materials

Enantiopure L-arginine amide hydrochloride (8) was purchased from Sigma Aldrich. Enantiopure PP-InsP4 and PP2-InsP4 were synthesized chemically using previously published procedures, with slight adjustments, e.g., pH values [21,22,27]. Enantiopure InsP3 and InsP4 standard compounds are commercially available and were obtained from SiChem as sodium salts. Description and synthesis of the compounds S1–S6 can be found within the Supplementary Materials.

2.2. NMR Measurements

NMR measurements were conducted on a Bruker Ascend 400 spectrometer with an Avance Neo console equipped with a Prodigy Cryoprobe. 31P-NMR (162 MHz) spectra were acquired at 300 K and recorded with 1H-decoupling (pulse program: zgpg30; size of FID: 64k; NS: 320; acquisition time: 0.5 s; spectral width: 405 ppm).
All NMR spectra were acquired in D2O with a sample concentration ranging from 2 to 4 mm (approx. 1 mg/mL). To enhance the resolution of the resonance signals, all samples were supplemented with ~50 mm Na2EDTA. The amount of L-Arg-NH2 hydrochloride (8) added during the experiments was in the range of 100- to 150-fold excess and was adjusted accordingly. The pH value was adjusted by adding TFA and aq. NaOH solution.

3. Results

3.1. Chemical Synthesis of InsP Model Compounds

In order to test the method, different model compounds were synthesized. Racemic 1,4,5-InsP3 (14) was synthesized over eight steps (Scheme 1). Starting from myo-inositol (1) different protecting groups were introduced to obtain the protected inositol 9 in accordance with the literature [28,29,30,31]. Subsequent protection of the 4-/6-position with an MEM group followed by selective cleavage of the silyl protecting groups gave triol 11. Threefold phosphorylation, followed by sequential cleavage of all protecting groups, furnished rac-1,4,5-InsP3 (14) in an overall yield of 6%.
As an InsP4 model compound, racemic 1,4,5,6-InsP4 (18) was synthesized over four steps (Scheme 2). In brief, ketalization of myo-inositol (1) furnished tetra-ol 15 in accordance with the literature [28]. Phosphorylation of tetra-ol 15 with AB-P-amidite S1 (see Supplementary Materials) afforded the AB-protected-InsP4 derivative 16. Basic cleavage of the AB-protecting groups, followed by an acidic cleavage of the cyclohexylidene ketal, gave rac-1,4,5,6-InsP4 (18) in an overall yield of 18%.
To explore if the chiral solvating agent could also be used to distinguish bisphosphonates, a nonhydrolyzable 4-/6-PCP-InsP5 derivative (23) was synthesized (Scheme 3) [25,26,32]. The 4- and 6-position of myo-inositol (1) is accessible by ortho-ester formation, followed by the selective introduction of a silyl protecting group to the 2-position. Monophosphorylation by using the PCP-phosphoramidite S2 (see Supplementary Materials) furnished the PCP derivative 20 as a mixture of diastereomers. Acidic deprotection and subsequent phosphorylation with an o-xylene-derived XE-phosphoramidite S3 (see Supplementary Materials) afforded the protected PCP-InsP5 derivative 21 [33]. Reaction control during the acidic deprotection was essential as the protected PCP group starts to migrate along the ring when the reaction time is too long. Global deprotection under hydrogenative conditions in the presence of a palladium catalyst furnished racemic 4-/6-PCP-InsP5 (23) after six steps in a yield of 5%.
Another novel compound that was synthesized in the context of this study is 5-PP-1/3-InsP1 (28). The molecule was made starting from myo-inositol (1) in nine steps (Scheme 4). It may serve to assign potential inositol pyrophosphates originating from early intermediates in inositol phosphate metabolism [34]. The PMB-protected InsP1 derivative 24 was synthesized over five steps according to the literature [21]. In the next step, one of the remaining two OH-groups was phosphorylated with XE-phosphoramidite S3 (see Supplementary Materials), resulting in InsP2-derivative 25 as a racemic mixture [33]. Selective deprotection of the 5-phosphate was achieved by removing the Fm protecting groups under basic conditions. The pyrophosphate was generated by phosphorylation with Bn-phosphoramidite S4 (see Supplementary Materials) [35]. 5-PP-InsP1 (28) was obtained by cleaving the remaining protecting groups under hydrogenative conditions.

3.2. Enantiomer Assignment by 31P-NMR Using a Chiral Solvating Agent

As discussed above, myo-inositol (1) harbors a mirror plane through the 2/5 positions of the molecule. Depending on the substitution pattern, different sets of signals were obtained for the InsPs and PP-InsPs in the 31P{1H}-NMR spectrum. The monophosphate signals appear in the range from 2 to −2 ppm. Signals of the pyrophosphates are visible in the range of −8 to −12 ppm. The shifts are strongly dependent on the pH value and the counterions [36].
In order to extend our enantiomer discrimination approach for InsP5 enantiomers, we measured various InsP and PP-InsP compounds [24]. Starting with 1,3- and 3,5-PP2-InsP4 (compounds S5 and S6, see Supplementary Materials), the enantiopure compounds were mixed to obtain racemic or chiral non-racemic mixtures. Without the presence of L-ArgNH2*HCl (8), we observed the typical signal set in the 31P-{1H}-NMR spectrum (Figure 3a). As expected, four singlet peaks in the monophosphate region are visible, each of them with an integral of 1. The diphosphate peaks are not clearly resolved, but because of the coupling between the phosphorus atoms, each of them should occur as a doublet and have an integral of 1. In the absence of a chiral solvating agent, the enantiomers cannot be distinguished by 31P-{1H}-NMR due to enantiotopicity. The addition of L-ArgNH2*HCl (8) creates a chiral environment that leads to diastereotopicity and a slight observable shift (Δppm up to 0.05 ppm) in some of the signals of each analyte (Figure 3a). By preparing samples with different compositions, it is possible to assign the signals to each individual enantiomer. For example, in a 2:1 mixture, only one set of the peaks is increasing in relative intensity. Raising the concentration of the opposite enantiomer leads to a corresponding increase in the other set of peaks (Figure 3b). As a control experiment, we also measured the enantiopure compounds in the presence of L-ArgNH2*HCl (8), and no splitting of the signals was observed (Figure 3c).
As the method was successful in analyzing PP2-InsP4 enantiomers, it was further applied to the unsymmetrical PP-InsP5 compounds. Without chiral additive, 4- and 6-PP-InsP5 (6 and 4) showed identical resonances in the 31P-NMR spectrum when mixed together, and only one set of signals was observed (Figure 4a). However, upon addition of L-ArgNH2*HCl (8), we observed the splitting of resonance signals to distinct subsets, both in the monophosphate region and for the signals of the pyrophosphate group (Δppm up to 0.1 ppm). By spiking with enantiopure compounds, we are able to make an absolute assignment (Figure 4c). In a control experiment, the enantiopure compounds were also measured in the presence of L-ArgNH2*HCl (8), and—as expected—only one set of signals was observed. The experiment was also conducted with enantiopure 1- and 3-PP-InsP5 (3 and 7) and again could be applied successfully for an absolute assignment of enantiomer identity (Figure 5). Although not all signals were equally well resolved, an unambiguous assignment of the absolute configuration requires only one out of the many signals available. Although minor impurities are visible in the spectra (e.g., InsP6), they do not impede the assignment of the absolute configuration.
After demonstrating the method’s general applicability to inositols containing seven or eight phosphates, we aimed to evaluate it for compounds with lower degrees of phosphorylation compared to InsP5. Therefore, a racemic mixture of 1,4,5,6-InsP4 (18) was synthesized (see Scheme 2) and 31P{1H}-NMR measurements were conducted. While the effectiveness of L-ArgNH2*HCl (8) was found to be largely independent of the pH value for InsP5, InsP7, and InsP8, a signal splitting into distinct subsets for InsP4 was only obtained within a narrow pH range. At a pH value between 7 and 8, we observed the expected splitting of the resonance signals (Δppm up to 0.06 ppm) in the presence of L-ArgNH2*HCl (8), whereas no splitting was observed in the absence of the chiral solvating agent (Figure 6a,b). By spiking with commercial enantiopure 1,4,5,6-InsP4 (18a), we were able to assign the signals to each respective enantiomer (Figure 6c). Outside of the pH range, the addition of the chiral solvating agent had no effect.
To further test the possibilities of the method regarding the number of phosphate groups, we conducted measurements with rac-1,4,5-InsP3 (14) under the same conditions mentioned above. The method was successful in resolving the enantiomer signals, but the pH adjustment was even more critical (Figure 7a). The desired splitting was only obtained at an exact pH of 6.4. The addition of the commercially available enantiomer allowed for the precise assignment of the respective signals in this case as well (Figure 7b).
After determining the limitations of the method with respect to the phosphorylation degree of InsPs, we also tested some non-natural InsP derivatives. One of them was 4-/6-PCP-InsP5 (23), which contains a non-hydrolyzable bisphosphonate (PCP) group substituting the diphosphate group. While these molecules do not occur in biology, we wanted to understand if the chiral solvating agent approach would also enable the determination of enantiomeric purity in such samples. Again, the addition of L-ArgNH2*HCl (8) resulted in the splitting of individual signals into subsets, independent of the pH value, allowing for the assignment of the respective enantiomers in principle (Figure 8a). However, we do not yet have an enantiomerically pure compound available to provide such an assignment. The other more unconventional InsP compound that we tested was the so far not naturally detected inositol pyrophosphate 5-PP-1/3-InsP1 (28) with only three phosphate groups (Scheme 4). Similarly to the previously observed trend with lowly phosphorylated InsPs, the method was highly pH-dependent, so the presence of a pyrophosphate group alone is not sufficient to render the method pH-independent. A signal splitting was only obtained within a narrow pH range between 7 and 8, and the peak-to-peak resolution was small, only observable for the phosphate ester peak at 3.4 ppm (Figure 8b). This will render the assignment of such putative isomers from biological samples difficult. Due to the unavailability of enantiomerically pure compounds, we are unable to provide a definitive assignment for 28.

4. Discussion

The accurate analysis and identification of regioisomers and enantiomers is a significant challenge but crucial for understanding the complex network of InsPs and PP-InsPs in biological systems [9,23,37,38]. Enantiomer assignment has traditionally been accomplished using crystal structures, enzymatic assays in combination with chemically synthesized standard compounds, and isotopically labeled myo-inositol (1) in combination with 13C-, 31P-, and two-dimensional-NMR measurements [14,15,18,19,20,21,22,23]. Here, we have demonstrated that assigning enantiomers can be achieved by using L-ArgNH2*HCl (8) as a chiral solvating agent in combination with 31P-NMR measurements. The method previously published for analyzing InsP5 enantiomers [24] has been extended to include highly phosphorylated PP-InsPs, lowly phosphorylated InsPs, and uncommon PCP-InsPs. The method showed excellent performance for the highly phosphorylated PP-InsPs without requiring any pH adjustment. However, for the lowly phosphorylated InsPs, pH adjustment during the measurement was necessary to improve resolution.
Our NMR-based method for enantiomer assignment can be used to assign the biologically relevant enantiomers of InsPs and PP-InsPs isolated from cells using, e.g., the TiO2 method and purified by SAX column chromatography or PAGE [39]. However, a significant amount of material is required due to the inherently low sensitivity of NMR spectroscopy, which can be a challenge in practice. In our earlier example of 1/3-OH InsP5, ca. 10 micrograms of material purified by PAGE was required for unambiguous enantiomer assignment. While this is a significant amount to isolate from biological samples, we and others have demonstrated that it is possible. Furthermore, the enantiomerically pure standard compounds need to be synthetically accessible, underscoring the importance of chemical synthesis in this interdisciplinary research area. An obvious advantage of the method described herein is that it relies on commercially available and cheap L-ArgNH2*HCl (8) that enables the resolution of enantiomeric pairs across a wide range of different inositol phosphorylation, pyrophosphorylation, and diphosphonate patterns. It is, therefore, a valuable addition to the current repertoire available to resolve the enantiomeric identity of InsPs and PP-InsPs.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biom13071150/s1, 1. General remarks, 2. Syntheses adapted from literature, 3. Synthesis of rac-1,4,5-InsP3 (14), 4. Synthesis of rac-1,4,5,6-InsP4 (18), 5. Synthesis of 4/6-PCP-InsP5 (23), 6. Synthesis of 5-PP-1/3-InsP1 (28), 7. Literature, 8. NMR spectra.

Author Contributions

K.R., N.J. and A.-S.U. synthesized compounds. K.R. measured NMR samples and analyzed data. K.R. and H.J.J. conceived the study. M.K. provided material. K.R. and H.J.J. wrote the manuscript. H.J.J. supervised the study. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the German Research Foundation (DFG) under Germany’s excellence strategy (CIBSS-EXC-2189-Project ID 390939984).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Additional data are available in the supplementary information and upon request from the authors.

Acknowledgments

We would like to thank Magres of the University of Freiburg for a significant amount of NMR measurement time.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bittner, T.; Wittwer, C.; Hauke, S.; Wohlwend, D.; Mundinger, S.; Dutta, A.K.; Bezold, D.; Dürr, T.; Friedrich, T.; Schultz, C.; et al. Photolysis of Caged Inositol Pyrophosphate InsP8 Directly Modulates Intracellular Ca2+Oscillations and Controls C2AB Domain Localization. J. Am. Chem. Soc. 2020, 142, 10606–10611. [Google Scholar] [CrossRef] [PubMed]
  2. Thota, S.G.; Bhandari, R. The Emerging Roles of Inositol Pyrophosphates in Eukaryotic Cell Physiology. J. Biosci. 2015, 40, 593–605. [Google Scholar] [CrossRef]
  3. Chakraborty, A.; Koldobskiy, M.A.; Bello, N.T.; Maxwell, M.; Potter, J.J.; Juluri, K.R.; Maag, D.; Kim, S.; Huang, A.S.; Dailey, M.J.; et al. Inositol Pyrophosphates Inhibit Akt Signaling, Thereby Regulating Insulin Sensitivity and Weight Gain. Cell 2010, 143, 897–910. [Google Scholar] [CrossRef] [PubMed]
  4. Illies, C.; Gromada, J.; Fiume, R.; Leibiger, B.; Yu, J.; Juhl, K.; Yang, S.-N.; Barma, D.K.; Falck, J.R.; Saiardi, A.; et al. Requirement of Inositol Pyrophosphates for Full Exocytotic Capacity in Pancreatic β Cells. Science 2007, 318, 1299–1302. [Google Scholar] [CrossRef] [PubMed]
  5. Lee, T.-S.; Lee, J.-Y.; Kyung, J.W.; Yang, Y.; Park, S.J.; Lee, S.; Pavlovic, I.; Kong, B.; Jho, Y.S.; Jessen, H.J.; et al. Inositol Pyrophosphates Inhibit Synaptotagmin-Dependent Exocytosis. Proc. Natl. Acad. Sci. USA 2016, 113, 8314–8319. [Google Scholar] [CrossRef] [PubMed]
  6. Hauke, S.; Dutta, A.K.; Eisenbeis, V.B.; Bezold, D.; Bittner, T.; Wittwer, C.; Thakor, D.; Pavlovic, I.; Schultz, C.; Jessen, H.J. Photolysis of Cell-Permeant Caged Inositol Pyrophosphates Controls Oscillations of Cytosolic Calcium in a β-Cell Line. Chem. Sci. 2019, 10, 2687–2692. [Google Scholar] [CrossRef] [PubMed]
  7. Szijgyarto, Z.; Garedew, A.; Azevedo, C.; Saiardi, A. Influence of Inositol Pyrophosphates on Cellular Energy Dynamics. Science 2011, 334, 802–805. [Google Scholar] [CrossRef]
  8. Irvine, R.F.; Schell, M.J. Back in the Water: The Return of the Inositol Phosphates. Nat. Rev. Mol. Cell. Biol. 2001, 2, 327–338. [Google Scholar] [CrossRef]
  9. Qiu, D.; Gu, C.; Liu, G.; Ritter, K.; Eisenbeis, V.B.; Bittner, T.; Gruzdev, A.; Seidel, L.; Bengsch, B.; Shears, S.B.; et al. Capillary Electrophoresis Mass Spectrometry Identifies New Isomers of Inositol Pyrophosphates in Mammalian Tissues. Chem. Sci. 2022, 14, 658–667. [Google Scholar] [CrossRef]
  10. Riemer, E.; Qiu, D.; Laha, D.; Harmel, R.K.; Gaugler, P.; Gaugler, V.; Frei, M.; Hajirezaei, M.R.; Laha, N.P.; Krusenbaum, L.; et al. ITPK1 Is an InsP6/ADP Phosphotransferase That Controls Phosphate Signaling in Arabidopsis. Mol. Plant 2021, 14, 1864–1880. [Google Scholar] [CrossRef]
  11. Wang, H.; Nair, V.S.; Holland, A.A.; Capolicchio, S.; Jessen, H.J.; Johnson, M.K.; Shears, S.B. Asp1 from Schizosaccharomyces Pombe Binds a [2Fe-2S]2+ Cluster Which Inhibits Inositol Pyrophosphate 1-Phosphatase Activity. Biochemistry 2015, 54, 6462–6474. [Google Scholar] [CrossRef]
  12. Mulugu, S.; Bai, W.; Fridy, P.C.; Bastidas, R.J.; Otto, J.C.; Dollins, D.E.; Haystead, T.A.; Ribeiro, A.A.; York, J.D. A Conserved Family of Enzymes That Phosphorylate Inositol Hexakisphosphate. Science 2007, 316, 106–109. [Google Scholar] [CrossRef] [PubMed]
  13. Laussmann, T.; Reddy, K.M.; Reddy, K.K.; Falck, J.R.; Vogel, G. Diphospho-Myo-Inositol Phosphates from Dictyostelium Identified as d-6-Diphospho-Myo-Inositol Pentakisphosphate and d-5,6-Bisdiphospho-Myo-Inositol Tetrakisphosphate. Biochem. J. 1997, 322, 31–33. [Google Scholar] [CrossRef] [PubMed]
  14. Wang, H.; Falck, J.R.; Hall, T.M.T.; Shears, S.B. Structural Basis for an Inositol Pyrophosphate Kinase Surmounting Phosphate Crowding. Nat. Chem. Biol. 2012, 8, 111–116. [Google Scholar] [CrossRef] [PubMed]
  15. Lin, H.; Fridy, P.C.; Ribeiro, A.A.; Choi, J.H.; Barma, D.K.; Vogel, G.; Falck, J.R.; Shears, S.B.; York, J.D.; Mayr, G.W. Structural Analysis and Detection of Biological Inositol Pyrophosphates Reveal That the Family of VIP/Diphosphoinositol Pentakisphosphate Kinases Are1/3-Kinases. J. Biol. Chem. 2009, 284, 1863–1872. [Google Scholar] [CrossRef]
  16. Losito, O.; Szijgyarto, Z.; Resnick, A.C.; Saiardi, A. Inositol Pyrophosphates and Their Unique Metabolic Complexity: Analysis by Gel Electrophoresis. PLoS ONE 2009, 4, e5580. [Google Scholar] [CrossRef]
  17. Qiu, D.; Wilson, M.S.; Eisenbeis, V.B.; Harmel, R.K.; Riemer, E.; Haas, T.M.; Wittwer, C.; Jork, N.; Gu, C.; Shears, S.B.; et al. Analysis of Inositol Phosphate Metabolism by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry. Nat. Commun. 2020, 11, 6035. [Google Scholar] [CrossRef]
  18. Laussmann, T.; Eujen, R.; Weisshuhn, C.M.; Thiel, U.; Vogel, G. Structures of Diphospho-Myo-Inositol Pentakisphosphate and Bisdiphospho-Myo-Inositol Tetrakisphosphate from Dictyostelium Resolved by NMR Analysis. Biochem. J. 1996, 315, 715–720. [Google Scholar] [CrossRef]
  19. Laha, D.; Parvin, N.; Hofer, A.; Giehl, R.F.H.; Fernandez-Rebollo, N.; Von Wirén, N.; Saiardi, A.; Jessen, H.J.; Schaaf, G. Arabidopsis ITPK1 and ITPK2 Have an Evolutionarily Conserved Phytic Acid Kinase Activity. ACS Chem. Biol. 2019, 14, 2127–2133. [Google Scholar] [CrossRef]
  20. Draškovič, P.; Saiardi, A.; Bhandari, R.; Burton, A.; Ilc, G.; Kovačevič, M.; Snyder, S.H.; Podobnik, M. Inositol Hexakisphosphate Kinase Products Contain Diphosphate and Triphosphate Groups. Chem. Biol. 2008, 15, 274–286. [Google Scholar] [CrossRef]
  21. Capolicchio, S.; Wang, H.; Thakor, D.T.; Shears, S.B.; Jessen, H.J. Synthesis of Densely Phosphorylated Bis-1,5-Diphospho-Myo-Inositol Tetrakisphosphate and Its Enantiomer by Bidirectional P-Anhydride Formation. Angew. Chem. Int. Ed. 2014, 53, 9508–9511. [Google Scholar] [CrossRef] [PubMed]
  22. Capolicchio, S.; Thakor, D.T.; Linden, A.; Jessen, H.J. Synthesis of Unsymmetric Diphospho-Inositol Polyphosphates. Angew. Chem. Int. Ed. 2013, 52, 6912–6916. [Google Scholar] [CrossRef]
  23. Nguyen Trung, M.; Kieninger, S.; Fandi, Z.; Qiu, D.; Liu, G.; Mehendale, N.K.; Saiardi, A.; Jessen, H.; Keller, B.; Fiedler, D. Stable Isotopomers of Myo-Inositol Uncover a Complex MINPP1-Dependent Inositol Phosphate Network. ACS Cent. Sci. 2022, 8, 1683–1694. [Google Scholar] [CrossRef] [PubMed]
  24. Blüher, D.; Laha, D.; Thieme, S.; Hofer, A.; Eschen-Lippold, L.; Masch, A.; Balcke, G.; Pavlovic, I.; Nagel, O.; Schonsky, A.; et al. A 1-Phytase Type III Effector Interferes with Plant Hormone Signaling. Nat. Commun. 2017, 8, 2159. [Google Scholar] [CrossRef]
  25. Wu, M.; Chong, L.S.; Capolicchio, S.; Jessen, H.J.; Resnick, A.C.; Fiedler, D. Elucidating Diphosphoinositol Polyphosphate Function with Nonhydrolyzable Analogues. Angew. Chem. Int. Ed. 2014, 53, 7192–7197. [Google Scholar] [CrossRef]
  26. Hostachy, S.; Utesch, T.; Franke, K.; Dornan, G.L.; Furkert, D.; Türkaydin, B.; Haucke, V.; Sun, H.; Fiedler, D. Dissecting the Activation of Insulin Degrading Enzyme by Inositol Pyrophosphates and Their Bisphosphonate Analogs. Chem. Sci. 2021, 12, 10696–10702. [Google Scholar] [CrossRef]
  27. Haas, T.M.; Mundinger, S.; Qiu, D.; Jork, N.; Ritter, K.; Dürr-Mayer, T.; Ripp, A.; Saiardi, A.; Schaaf, G.; Jessen, H.J. Stable Isotope Phosphate Labelling of Diverse Metabolites Is Enabled by a Family of 18O-Phosphoramidites**. Angew. Chem. Int. Ed. 2022, 61, e202112457. [Google Scholar] [CrossRef]
  28. Kiely, D.E.; Abruscato, G.J.; Baburao, V. A Synthesis of (±)Myo-Inositol 1-Phosphate. Carbohydr. Res. 1974, 34, 307–313. [Google Scholar] [CrossRef]
  29. Rukavishnikov, A.V.; Ryan, M.; Griffith, O.H.; Keana, J.F.W. A Chromogenic Substrate for the Continuous Assay of Mammalian Phosphoinositide-Specific Phospholipase C. Bioorg. Med. Chem. Lett. 1997, 7, 1239–1242. [Google Scholar] [CrossRef]
  30. Subramanian, D.; Laketa, V.; Müller, R.; Tischer, C.; Zarbakhsh, S.; Pepperkok, R.; Schultz, C. Activation of Membrane-Permeant Caged PtdIns(3)P Induces Endosomal Fusion in Cells. Nat. Chem. Biol. 2010, 6, 324–326. [Google Scholar] [CrossRef]
  31. Jessen, H.J.; Schulz, T.; Balzarini, J.; Meier, C. Bioreversible Protection of Nucleoside Diphosphates. Angew. Chem. Int. Ed. 2008, 47, 8719–8722. [Google Scholar] [CrossRef] [PubMed]
  32. Furkert, D.; Hostachy, S.; Nadler-Holly, M.; Fiedler, D. Triplexed Affinity Reagents to Sample the Mammalian Inositol Pyrophosphate Interactome. Cell Chem. Biol. 2020, 27, 1097–1108.e4. [Google Scholar] [CrossRef] [PubMed]
  33. Zhang, H.; Thompson, J.; Prestwich, G.D. A Scalable Synthesis of the IP7 Isomer, 5-PP-Ins(1,2,3,4,6)P5. Org. Lett. 2009, 11, 1551–1554. [Google Scholar] [CrossRef]
  34. Desfougères, Y.; Wilson, M.S.C.; Laha, D.; Miller, G.J.; Saiardi, A. ITPK1 Mediates the Lipid-Independent Synthesis of Inositol Phosphates Controlled by Metabolism. Proc. Natl. Acad. Sci. USA 2019, 116, 24551–24561. [Google Scholar] [CrossRef] [PubMed]
  35. Das, S.; Parekh, N.; Mondal, B.; Gupta, S.S. Controlled Synthesis of End-Functionalized Mannose-6-Phosphate Glycopolypeptides for Lysosome Targeting. ACS Macro. Lett. 2016, 5, 809–813. [Google Scholar] [CrossRef] [PubMed]
  36. Kurz, L.; Schmieder, P.; Veiga, N.; Fiedler, D. One Scaffold, Two Conformations: The Ring-Flip of the Messenger InsP8 Occurs under Cytosolic Conditions. Biomolecules 2023, 13, 645. [Google Scholar] [CrossRef]
  37. Liu, G.; Riemer, E.; Schneider, R.; Cabuzu, D.; Bonny, O.; Wagner, C.A.; Qiu, D.; Saiardi, A.; Strauss, A.; Lahaye, T.; et al. The Phytase RipBL1 Enables the Assignment of a Specific Inositol Phosphate Isomer as a Structural Component of Human Kidney Stones. RSC Chem. Biol. 2023, 4, 300–309. [Google Scholar] [CrossRef]
  38. Qiu, D.; Eisenbeis, V.B.; Saiardi, A.; Jessen, H.J. Absolute Quantitation of Inositol Pyrophosphates by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry. J. Vis. Exp. 2021, 174, e62847. [Google Scholar] [CrossRef]
  39. Wilson, M.; Saiardi, A. Inositol Phosphates Purification Using Titanium Dioxide Beads. Bio Protoc. 2018, 8, e2959. [Google Scholar] [CrossRef]
Biomolecules 13 01150 g001
Figure 1. Illustration to distinguish chiral and achiral PP-InsP5 isomers. Introduction of pyrophosphates outside of the mirror plane leads to the formation of enantiomeric pairs. If the pyrophosphates are on the mirror plane, the molecules are achiral.
Figure 1. Illustration to distinguish chiral and achiral PP-InsP5 isomers. Introduction of pyrophosphates outside of the mirror plane leads to the formation of enantiomeric pairs. If the pyrophosphates are on the mirror plane, the molecules are achiral.
Biomolecules 13 01150 g001
Biomolecules 13 01150 g002
Figure 2. Structure of the chiral solvating agent L-arginine amide hydrochloride (8, L-ArgNH2* HCl).
Figure 2. Structure of the chiral solvating agent L-arginine amide hydrochloride (8, L-ArgNH2* HCl).
Biomolecules 13 01150 g002
Biomolecules 13 01150 sch001
Scheme 1. Synthesis of racemic rac-1,4,5-InsP3. Reagents and conditions: (a) MEM-Cl (10.0 eq.), DIPEA (15.0 eq.), CHCl3, 70 °C, 3d. (b) TBAF, THF, 70 °C, 3d. (c) Compound 11 (1.0 eq.), AB-P-amidite S1 (4.0 eq.), ETT (4.0 eq.), MeCN, rt, 30 min; then mCPBA (4.0 eq.), 0 °C, 10 min. (d) Piperidine/DMF (1:4), rt, 1.5 h. (e) HCl, EtOH, rt, 3d. Abbreviations: MEM-Cl = 2-Methoxyethoxymethyl chloride; DIPEA = N,N-Diisopropylethylamine; TBAF = Tetrabutylammonium fluoride; AB-P-amidite = Acetoxybenzyl-N,N-diisopropylamino phosphoramidite; ETT = 5-Ethylthio-1H-tetrazole; mCPBA = meta-Chloroperoxybenzoic acid; DMF = Dimethylformamide.
Scheme 1. Synthesis of racemic rac-1,4,5-InsP3. Reagents and conditions: (a) MEM-Cl (10.0 eq.), DIPEA (15.0 eq.), CHCl3, 70 °C, 3d. (b) TBAF, THF, 70 °C, 3d. (c) Compound 11 (1.0 eq.), AB-P-amidite S1 (4.0 eq.), ETT (4.0 eq.), MeCN, rt, 30 min; then mCPBA (4.0 eq.), 0 °C, 10 min. (d) Piperidine/DMF (1:4), rt, 1.5 h. (e) HCl, EtOH, rt, 3d. Abbreviations: MEM-Cl = 2-Methoxyethoxymethyl chloride; DIPEA = N,N-Diisopropylethylamine; TBAF = Tetrabutylammonium fluoride; AB-P-amidite = Acetoxybenzyl-N,N-diisopropylamino phosphoramidite; ETT = 5-Ethylthio-1H-tetrazole; mCPBA = meta-Chloroperoxybenzoic acid; DMF = Dimethylformamide.
Biomolecules 13 01150 sch001
Biomolecules 13 01150 sch002
Scheme 2. Synthesis of rac-1/3–4,5,6-InsP4 (18). Reagents and conditions: (a) Cyclohexanone (15 eq.), pTsOH (0.04 eq) benzene/DMF (1:1), reflux, 24 h. (b) Compound 15 (1.0 eq), AB-P-amidite S1 (7.5 eq), DCI (7.5 eq), MeCN, rt, 1 h; then mCPBA (7.5 eq), 0 °C, 10 min. (c) Piperidine/DMF (2:1), rt, 2 h. (d) TFA (15 eq), H2O, 60 °C, 1 h; then NEt3 (15 eq). Abbreviations: pTsOH = p-Toluenesulfonic acid; DMF = Dimethylformamide; AB-P-amidite = Acetoxybenzyl-N,N-diisopropylamino phosphoramidite; DCI = 4,5-Dicyanoimidazole; mCPBA = meta-Chloroperoxybenzoic acid; TFA = Trifluoroacetic acid.
Scheme 2. Synthesis of rac-1/3–4,5,6-InsP4 (18). Reagents and conditions: (a) Cyclohexanone (15 eq.), pTsOH (0.04 eq) benzene/DMF (1:1), reflux, 24 h. (b) Compound 15 (1.0 eq), AB-P-amidite S1 (7.5 eq), DCI (7.5 eq), MeCN, rt, 1 h; then mCPBA (7.5 eq), 0 °C, 10 min. (c) Piperidine/DMF (2:1), rt, 2 h. (d) TFA (15 eq), H2O, 60 °C, 1 h; then NEt3 (15 eq). Abbreviations: pTsOH = p-Toluenesulfonic acid; DMF = Dimethylformamide; AB-P-amidite = Acetoxybenzyl-N,N-diisopropylamino phosphoramidite; DCI = 4,5-Dicyanoimidazole; mCPBA = meta-Chloroperoxybenzoic acid; TFA = Trifluoroacetic acid.
Biomolecules 13 01150 sch002
Biomolecules 13 01150 sch003
Scheme 3. Synthesis of racemic 4/6-PCP-InsP5 (23). Reagents and conditions: (a) Compound 19 (2.8 eq), PCP-P-amidite S2 (1.0 eq), ETT (1.1 eq), MeCN, rt, 1 h; then tBuOOH (2.0 eq), 0 °C, 15 min. (b) pTsOH, MeOH, 60 °C, 3 h. (c) Compound 21 (1.0 eq), XE-P-amidite S3 (16 eq.), ETT (16 eq.), CH2Cl2, rt, 2 h; then mCPBA (16 eq.), rt, 15 min. (d) NaHCO3 (13 eq.), Pd/C, H2 (40 bar), rt, 2 h. Abbreviations: ETT = 5-Ethylthio-1H-tetrazole; tBuOOH = tert-Butyl hydroperoxide; pTsOH = p-Toluenesulfonic acid; XE-P-amidite = o-xylylene-N,N-diisopropylamino phosphoramidite; mCPBA = meta-Chloroperoxybenzoic acid.
Scheme 3. Synthesis of racemic 4/6-PCP-InsP5 (23). Reagents and conditions: (a) Compound 19 (2.8 eq), PCP-P-amidite S2 (1.0 eq), ETT (1.1 eq), MeCN, rt, 1 h; then tBuOOH (2.0 eq), 0 °C, 15 min. (b) pTsOH, MeOH, 60 °C, 3 h. (c) Compound 21 (1.0 eq), XE-P-amidite S3 (16 eq.), ETT (16 eq.), CH2Cl2, rt, 2 h; then mCPBA (16 eq.), rt, 15 min. (d) NaHCO3 (13 eq.), Pd/C, H2 (40 bar), rt, 2 h. Abbreviations: ETT = 5-Ethylthio-1H-tetrazole; tBuOOH = tert-Butyl hydroperoxide; pTsOH = p-Toluenesulfonic acid; XE-P-amidite = o-xylylene-N,N-diisopropylamino phosphoramidite; mCPBA = meta-Chloroperoxybenzoic acid.
Biomolecules 13 01150 sch003
Biomolecules 13 01150 sch004
Scheme 4. Synthesis of racemic 5-PP-1/3-InsP1 (28). Reagents and conditions: (a) Compound 24 (2.5 eq.), XE-P-amidite (S3) (1.0 eq), ETT (1.1 eq.), MeCN/CH2Cl2, rt, 1 h; then tBuOOH (2.0 eq.), 0 °C, 30 min. (b) MeCN/piperidine (2:1), rt, 3d. (c) Compound 26 (1.0 eq), Bn-P-amidite (S4) (1.1 eq.), ETT (4 eq.), rt, 2 h; then tBuOOH (2.0 eq.), 0 °C, 30 min. (d) NaHCO3 (5.0 eq.), Pd/C, H2 (35 bar), rt, 4d. Abbreviations: XE-P-amidite = o-xylylene-N,N-diisopropylamino phosphoramidite; ETT = 5-Ethylthio-1H-tetrazole; tBuOOH = tert-Butyl hydroperoxide; Bn-P-amidite = Benzyl-N,N-diisopropylamino phosphoramidite; Fm = Fluorenmethyl.
Scheme 4. Synthesis of racemic 5-PP-1/3-InsP1 (28). Reagents and conditions: (a) Compound 24 (2.5 eq.), XE-P-amidite (S3) (1.0 eq), ETT (1.1 eq.), MeCN/CH2Cl2, rt, 1 h; then tBuOOH (2.0 eq.), 0 °C, 30 min. (b) MeCN/piperidine (2:1), rt, 3d. (c) Compound 26 (1.0 eq), Bn-P-amidite (S4) (1.1 eq.), ETT (4 eq.), rt, 2 h; then tBuOOH (2.0 eq.), 0 °C, 30 min. (d) NaHCO3 (5.0 eq.), Pd/C, H2 (35 bar), rt, 4d. Abbreviations: XE-P-amidite = o-xylylene-N,N-diisopropylamino phosphoramidite; ETT = 5-Ethylthio-1H-tetrazole; tBuOOH = tert-Butyl hydroperoxide; Bn-P-amidite = Benzyl-N,N-diisopropylamino phosphoramidite; Fm = Fluorenmethyl.
Biomolecules 13 01150 sch004
Biomolecules 13 01150 g003
Figure 3. (a) 31P{1H}-NMR spectra of a 1:1 mixture of 1,5- and 3,5-PP2-InsP4 (compounds S5 and S6) without chiral solvating agent and with L-ArgNH2*HCl (8) as a chiral solvating agent. In the presence of L-ArgNH2*HCl (8), the resonance signals caused by the monophosphates are split into two distinct signal sets. (b) 31P{1H}-NMR spectra of a 2:1 mixture and a 1:2 mixture of 1,5- and 3,5-PP2-InsP4 (compounds S5 and S6) in the presence of L-ArgNH2*HCl (8). Only a single resolved peak, e.g., in the monophosphate region, is required for an assignment of the individual enantiomers. (c) 31P{1H}-NMR spectra of 1,5- and 3,5-PP2-InsP4 (compounds S5 and S6) in the presence of L-ArgNH2*HCl (8). Spectra of the enantiomerically pure compounds do not show any splitting of the resonance signals with the chiral solvating agent.
Figure 3. (a) 31P{1H}-NMR spectra of a 1:1 mixture of 1,5- and 3,5-PP2-InsP4 (compounds S5 and S6) without chiral solvating agent and with L-ArgNH2*HCl (8) as a chiral solvating agent. In the presence of L-ArgNH2*HCl (8), the resonance signals caused by the monophosphates are split into two distinct signal sets. (b) 31P{1H}-NMR spectra of a 2:1 mixture and a 1:2 mixture of 1,5- and 3,5-PP2-InsP4 (compounds S5 and S6) in the presence of L-ArgNH2*HCl (8). Only a single resolved peak, e.g., in the monophosphate region, is required for an assignment of the individual enantiomers. (c) 31P{1H}-NMR spectra of 1,5- and 3,5-PP2-InsP4 (compounds S5 and S6) in the presence of L-ArgNH2*HCl (8). Spectra of the enantiomerically pure compounds do not show any splitting of the resonance signals with the chiral solvating agent.
Biomolecules 13 01150 g003
Biomolecules 13 01150 g004
Figure 4. (a) 31P{1H}-NMR-spectra of an approx. 1:1 mixture of 4- and 6-PP-InsP5 (6 and 4) without chiral solvating agent and with L-ArgNH2*HCl (8). In the presence of L-ArgNH2*HCl (8), the resonance signals caused by the monophosphates, as well as the signals of the pyrophosphates, are split into two signal sets. (b) 31P{1H}-NMR-spectra of enantiopure 4- and 6-PP-InsP5 with L-ArgNH2*HCl (8). Only one set of signals was observed. (c) 31P{1H}-NMR spectra of an approx. 2:1 mixture and an approx. 1:2 mixture of 4- and 6-PP-InsP5 (6 and 4) in the presence of L-ArgNH2*HCl (8). By comparing the spectra, the assignment of the absolute structure is possible.
Figure 4. (a) 31P{1H}-NMR-spectra of an approx. 1:1 mixture of 4- and 6-PP-InsP5 (6 and 4) without chiral solvating agent and with L-ArgNH2*HCl (8). In the presence of L-ArgNH2*HCl (8), the resonance signals caused by the monophosphates, as well as the signals of the pyrophosphates, are split into two signal sets. (b) 31P{1H}-NMR-spectra of enantiopure 4- and 6-PP-InsP5 with L-ArgNH2*HCl (8). Only one set of signals was observed. (c) 31P{1H}-NMR spectra of an approx. 2:1 mixture and an approx. 1:2 mixture of 4- and 6-PP-InsP5 (6 and 4) in the presence of L-ArgNH2*HCl (8). By comparing the spectra, the assignment of the absolute structure is possible.
Biomolecules 13 01150 g004
Biomolecules 13 01150 g005
Figure 5. 31P{1H}-NMR-spectra of 1- and 3-PP-InsP5 (3 and 7) at different mixing ratios in the presence of L-ArgNH2*HCl (8). By comparing distinct peaks, e.g., those highlighted in the green boxes, enantiomer assignment is possible.
Figure 5. 31P{1H}-NMR-spectra of 1- and 3-PP-InsP5 (3 and 7) at different mixing ratios in the presence of L-ArgNH2*HCl (8). By comparing distinct peaks, e.g., those highlighted in the green boxes, enantiomer assignment is possible.
Biomolecules 13 01150 g005
Biomolecules 13 01150 g006
Figure 6. (a) 31P-{1H}-NMR spectrum of racemic 1/3,4,5,6-InsP4 (18) without L-ArgNH2*HCl (8). (b) 31P-{1H}-NMR spectrum of racemic 1/3,4,5,6-InsP4 (18) in the presence of L-ArgNH2*HCl (8). (c) 31P-{1H}-NMR spectrum of racemic 1/3,4,5,6-InsP4 in the presence of L-ArgNH2*HCl (8) spiked with commercial enantiopure 1,4,5,6-InsP4 (18a). By comparing distinct peaks, e.g., those highlighted in the green box, enantiomer assignment is possible.
Figure 6. (a) 31P-{1H}-NMR spectrum of racemic 1/3,4,5,6-InsP4 (18) without L-ArgNH2*HCl (8). (b) 31P-{1H}-NMR spectrum of racemic 1/3,4,5,6-InsP4 (18) in the presence of L-ArgNH2*HCl (8). (c) 31P-{1H}-NMR spectrum of racemic 1/3,4,5,6-InsP4 in the presence of L-ArgNH2*HCl (8) spiked with commercial enantiopure 1,4,5,6-InsP4 (18a). By comparing distinct peaks, e.g., those highlighted in the green box, enantiomer assignment is possible.
Biomolecules 13 01150 g006
Biomolecules 13 01150 g007
Figure 7. (a) 31P-{1H}-NMR spectrum of rac-1,4,5-InsP3 (14) in the presence of L-ArgNH2*HCl (8). (b) 31P-{1H}-NMR spectrum of rac-1,4,5,-InsP3 in the presence of L-ArgNH2*HCl (8) spiked with commercial enantiopure 1,4,5-InsP3 (14a).
Figure 7. (a) 31P-{1H}-NMR spectrum of rac-1,4,5-InsP3 (14) in the presence of L-ArgNH2*HCl (8). (b) 31P-{1H}-NMR spectrum of rac-1,4,5,-InsP3 in the presence of L-ArgNH2*HCl (8) spiked with commercial enantiopure 1,4,5-InsP3 (14a).
Biomolecules 13 01150 g007
Biomolecules 13 01150 g008
Figure 8. (a) 31P-{1H}-NMR spectrum of racemic 4/6-PCP-InsP5 (23) without additive and in the presence L-ArgNH2*HCl (8). (b) 31P-{1H}-NMR spectrum of racemic 5-PP-1/3-InsP1 (28) without additive and in the presence L-ArgNH2*HCl (8).
Figure 8. (a) 31P-{1H}-NMR spectrum of racemic 4/6-PCP-InsP5 (23) without additive and in the presence L-ArgNH2*HCl (8). (b) 31P-{1H}-NMR spectrum of racemic 5-PP-1/3-InsP1 (28) without additive and in the presence L-ArgNH2*HCl (8).
Biomolecules 13 01150 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ritter, K.; Jork, N.; Unmüßig, A.-S.; Köhn, M.; Jessen, H.J. Assigning the Absolute Configuration of Inositol Poly- and Pyrophosphates by NMR Using a Single Chiral Solvating Agent. Biomolecules 2023, 13, 1150. https://doi.org/10.3390/biom13071150

AMA Style

Ritter K, Jork N, Unmüßig A-S, Köhn M, Jessen HJ. Assigning the Absolute Configuration of Inositol Poly- and Pyrophosphates by NMR Using a Single Chiral Solvating Agent. Biomolecules. 2023; 13(7):1150. https://doi.org/10.3390/biom13071150

Chicago/Turabian Style

Ritter, Kevin, Nikolaus Jork, Anne-Sophie Unmüßig, Maja Köhn, and Henning J. Jessen. 2023. "Assigning the Absolute Configuration of Inositol Poly- and Pyrophosphates by NMR Using a Single Chiral Solvating Agent" Biomolecules 13, no. 7: 1150. https://doi.org/10.3390/biom13071150

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop